Stereotaxis, Inc.
STXS- Exchange
- NYSE
- Industry
- Electromedical & Electrotherapeutic Apparatus
- SEC CIK
- 0001289340
No open-market purchases or sales by Stereotaxis, Inc. insiders were filed in the last 90 days; 108 institutions reported holding it in 13F filings for Q2 2026, worth $74.1M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Stereotaxis, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 59 | 1 | 58 | 0 |
| Shares | 41.1M | 10.0K | 37.9M | −3.16M (−7.7%) |
| Value | $61.1M | $15.3K | $59.9M | −$1.19M (−1.9%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (5)
Institutions that held Stereotaxis, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 77,879 | $123.0K | 0.00% |
| LPL Financial LLC | 34,183 | $54.0K | 0.00% |
| Barclays PLC | 22,056 | $34.8K | 0.00% |
| Qube Research & Technologies Ltd | 10,945 | $17.3K | 0.00% |
| Citigroup Inc | 9,133 | $14.4K | 0.00% |
Sold out (5)
Institutions that held Stereotaxis, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Opaleye Management Inc. | 3,074,995 | $2.95M |
| Two Sigma Advisers, LP | 97,200 | $148.7K |
| Gsa Capital Partners LLP | 84,790 | $130.0K |
| Two Sigma Investments, LP | 44,328 | $67.8K |
| Tower Research Capital LLC (TRC) | 2,284 | $3.50K |
Not filed for Q3 2023 yet (1)
Institutions that held Stereotaxis, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| BDO Wealth Advisors, LLC | 10,000 | $15.3K |